Holen Sie sich die Stockscreener-App
6.0903
5.73%
-0.3697
Schlusskurs vom Vortag:
$6.46
Offen:
$6.42
24-Stunden-Volumen:
388.95K
Relative Volume:
0.16
Marktkapitalisierung:
$1.24B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-54.70M
KGV:
-18.46
EPS:
-0.33
Netto-Cashflow:
$-51.36M
1W Leistung:
+4.64%
1M Leistung:
-5.43%
6M Leistung:
+144.58%
1J Leistung:
+111.46%
1-Tages-Spanne:
$6.0801
$6.42
1-Wochen-Bereich:
$5.60
$6.49
52-Wochen-Spanne:
$1.89
$7.005
Savara Inc Stock (SVRA) Company Profile
Firmenname
Savara Inc
Sektor
Branche
Telefon
51285113796
Adresse
6836 BEE CAVE ROAD, AUSTIN, TX
Vergleichen Sie SVRA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
6.085 | 1.31B | 0 | -54.70M | -51.36M | -0.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.89 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.65 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
813.59 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.52 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-08-15 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-05-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-12-20 | Eingeleitet | Wells Fargo | Overweight |
| 2024-11-13 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-02-15 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-11-07 | Eingeleitet | Guggenheim | Buy |
| 2023-05-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-03-31 | Herabstufung | Jefferies | Buy → Hold |
| 2021-03-16 | Eingeleitet | Piper Sandler | Overweight |
| 2021-03-15 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-13 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-13 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-13 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2018-08-13 | Fortgesetzt | ROTH Capital | Neutral |
| 2018-01-03 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-09-27 | Fortgesetzt | ROTH Capital | Buy |
| 2017-09-22 | Eingeleitet | Jefferies | Buy |
| 2017-09-11 | Eingeleitet | JMP Securities | Mkt Outperform |
Alle ansehen
Savara Inc Aktie (SVRA) Neueste Nachrichten
CEO Moves: Does Star Equity Holdings Inc have a competitive edgeLong Setup & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Rare lung drug nears FDA decision as PANTHERx, Savara seal US deal - MSN
Rare Lung Drug Nears FDA Decision as PANTHERx, Savara Seal U.S. Deal - mychesco.com
Savara Secures $75 Million Royalty Deal to Back Potential MOLBREEVI Launch - MSN
Day Trade: What is the dividend yield of LIVEJuly 2025 Breakouts & Risk Managed Investment Strategies - baoquankhu1.vn
Aug Opening: Should I trade or invest in Savara Inc2025 Institutional Moves & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Savara Announces New Employment Inducement Grant - Business Wire
What Savara (SVRA)'s Exclusive PANTHERx MOLBREEVI Distribution Deal Means For Shareholders - simplywall.st
Aug Opening: Will Savara Inc benefit from government policyRate Cut & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Savara Reports 2024 Financial Results and Provides Updates on MOLBREEVI Progress - MSN
Value Recap: Can Savara Inc disrupt its industryJobs Report & Weekly Watchlist of Top Performers - baoquankhu1.vn
Savara Highlights Autoimmune PAP Burden in Updated Presentation - TipRanks
Lobbying Update: $30,000 of SAVARA INC. lobbying was just disclosed - Quiver Quantitative
With 37% stake, Savara Inc. (NASDAQ:SVRA) seems to have captured institutional investors' interest - Yahoo Finance
Savara Inc. (NASDAQ:SVRA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Savara Inc. Announces Equity Awards for New Employees - MSN
Savara Inc. Grants Inducement Awards to New Employees with Stock Options & RSUs - MSN
How big funds are accumulating Savara Inc. (YB4P) stock2025 Price Action Summary & Capital Protection Trade Alerts - Улправда
Why Savara Inc. stock is favored by top institutions2025 Stock Rankings & Growth Focused Entry Reports - ulpravda.ru
How Savara Inc. stock compares to growth peers2025 Institutional Moves & AI Optimized Trading Strategy Guides - Улправда
The Bull Case For Savara (SVRA) Could Change Following Exclusive MOLBREEVI Distribution Deal With PANTHERx - simplywall.st
Market Fear: Will Savara Inc. stock outperform growth indexesMarket Risk Analysis & Smart Swing Trading Alerts - Улправда
How Savara Inc. stock benefits from global expansionJuly 2025 Movers & Fast Gaining Stock Strategy Reports - Улправда
Will Savara Inc. stock outperform growth indexes2025 Market WrapUp & AI Powered Market Trend Analysis - ulpravda.ru
Will Savara Inc. stock outperform tech sector in 20252025 Price Momentum & Daily Price Action Insights - Улправда
How Savara Inc. (YB4P) stock compares with top peersProduct Launch & Technical Confirmation Alerts - Улправда
PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI - PharmiWeb.com
Savara : Corporate Presentation - MarketScreener
Can Savara Inc. stock beat market expectations this quarterJuly 2025 Review & Fast Gain Stock Trading Tips - ulpravda.ru
PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI* - Yahoo Finance Australia
Will Savara Inc. stock sustain high P E ratiosPortfolio Performance Summary & AI Forecasted Stock Moves - ulpravda.ru
Will Savara Inc. (YB4P) stock rise with strong economyBuy Signal & Fast Exit Strategy with Risk Control - Улправда
Will Savara Inc. stock reach all time highs in 20252025 Market Sentiment & Safe Investment Capital Preservation Plans - ulpravda.ru
Aug Volume: How Savara Inc stock compares to growth peersRisk Management & Growth Focused Investment Plans - moha.gov.vn
Will Savara Inc. stock benefit from sector rotation2026 world cup usa national team group stage key players transition play expert forecast insights - ulpravda.ru
FDA clock restarts: Savara refiles MOLBREEVI for rare lung disease - MSN
Oppenheimer Assumes Coverage of Savara (SVRA) With an Outperform Rating - MSN
FDA Clock Restarts: Savara Refiles MOLBREEVI for Rare Lung Disease - MyChesCo
Savara (NASDAQ:SVRA) Shares Down 5.1%Should You Sell? - MarketBeat
Savara Inc. (NASDAQ:SVRA) Short Interest Up 33.1% in December - MarketBeat
Death Cross: Is Savara Inc stock a defensive play in 2025Market Growth Summary & Safe Capital Growth Plans - moha.gov.vn
Savara Heads to JPMorgan Conference as Investors Watch Rare Lung Drug - MyChesCo
With 37% Ownership in Savara Inc. (NASDAQ:SVRA), Institutional Investors Have a Lot Riding on the Business - 富途牛牛
Swedbank AB Takes $1.96 Million Position in Savara Inc. $SVRA - MarketBeat
Gap Down: Is Savara Inc YB4P stock a buy for dividend portfolios2025 Trade Ideas & AI Based Buy and Sell Signals - moha.gov.vn
How Savara Inc. stock reacts to Fed rate cutsSector Performance Review & Your Free Entry to Smart Investing Starts Here - bollywoodhelpline.com
Savara price target raised to $10 from $8 at HC Wainwright - MSN
Savara Inc. ticks higher amid takeover speculation - MSN
Finanzdaten der Savara Inc-Aktie (SVRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.38%
1.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):